MINYANVILLE ORIGINAL Dynavax Technologies' (NASDAQ:DVAX) stock is plummeting Friday after a panel of government advisers said it wasn’t convinced that the company’s experimental vaccine for hepatitis B was safe.   The advisers to the Food and Drug Administration voted 8-5 saying there wasn’t enough study data from the company to show Heplisav was safe. The advisers also voted 13-1 to support the apparent effectiveness of the vaccine in treating adults. The FDA will consider the panel recommendations and will make a decision on a possible approval by February 24. It’s not likely that the FDA is going to approve ...